PNC-27
p53-MDM2 Peptide
PNC-27 is a synthetic anti-cancer peptide consisting of a sequence derived from the p53 tumor suppressor protein (residues 12-26) linked to a membrane-penetrating (HDM-2 binding) domain that selectively targets and destroys cancer cells expressing HDM-2 (Human Double Minute 2) on their surface membrane. Unlike most chemotherapeutic agents, PNC-27 induces rapid membranolysis (membrane destruction) and necrosis specifically in cancer cells while leaving normal cells unaffected due to the absence of surface HDM-2 in healthy tissue. It remains in the preclinical research stage with no human clinical trials completed.
Mechanism of Action
Chimeric peptide combining an HDM-2 binding domain with a cell-penetrating sequence. Selectively targets cells with membrane-associated HDM-2 (overexpressed in many cancer cells), creating pores that trigger necrosis. Spares normal cells lacking surface HDM-2.
Research Protocols
For research purposes only. Not medical advice.
Research is primarily in vitro and animal models. No established human dosing protocols. Cancer research studies used 50-200mcg/ml in cell culture. In vivo studies used local injection into tumors.
Research Notes
Clinical Research Status
PNC-27 has been extensively studied in preclinical cell culture and animal models by the research group of Dr. Ehsan Ehsanipour and collaborators, with publications spanning multiple cancer cell types over the past two decades. No human clinical trials have been registered or completed, and the compound remains firmly in the laboratory research phase. The selective cytotoxicity demonstrated in vitro has generated significant interest, but translation to clinical use faces challenges including peptide stability, delivery, pharmacokinetics, and manufacturing at therapeutic scale.
Key Published Findings
Studies demonstrate that PNC-27 induces rapid necrosis (within hours) in multiple cancer cell lines including breast (MDA-MB-231, MCF-7), pancreatic (MIA PaCa-2), and leukemia cells while showing no toxicity to normal cells at equivalent concentrations. The mechanism involves binding to HDM-2 protein aberrantly expressed on the surface of cancer cells (but not normal cells), leading to membrane pore formation, loss of membrane integrity, and necrotic cell death. Importantly, the cytotoxic mechanism is independent of p53 status in the cancer cell, meaning it can kill p53-mutant cancers that are resistant to conventional therapies.
Safety Profile
In vitro studies consistently show that PNC-27 has no cytotoxic effect on normal human fibroblasts, lymphocytes, or other non-transformed cells at concentrations that kill cancer cells. Animal studies using xenograft tumor models have not reported significant systemic toxicity at effective anti-tumor doses. However, comprehensive toxicology studies, pharmacokinetic profiling, and maximum tolerated dose determinations have not been published, and the peptide's behavior in complex human physiology remains unknown.
Comparison to Related Compounds
PNC-27 is unique among anti-cancer peptides in targeting a specific oncogenic surface marker (HDM-2) rather than general differences in membrane charge or composition that other antimicrobial/anticancer peptides exploit. Unlike conventional chemotherapy which kills rapidly dividing cells indiscriminately, PNC-27's selectivity is based on a molecular marker of malignant transformation. Compared to antibody-drug conjugates (ADCs) and immune checkpoint inhibitors, PNC-27 represents a simpler molecular approach but faces similar challenges in tumor penetration and peptide drug delivery.
Community Observations
PNC-27 generates significant interest in alternative cancer research communities due to its selectivity and novel mechanism, though access outside of research settings is essentially impossible. The peptide is occasionally discussed in online forums alongside other experimental cancer compounds, with patients and advocates expressing frustration at the slow pace of clinical translation. Legitimate researchers caution that impressive in vitro results do not guarantee clinical efficacy, as many promising cancer compounds fail in the transition from cell culture to human patients.
Half-Life
~Unknown
Reconstitution
Sterile PBS or bacteriostatic water
Storage
Lyophilized
Store at -20C. Extremely sensitive to degradation.
Reconstituted
Prepare fresh. Use within 24 hours.
US Legal Status
Also Known As
PeptideVault provides research-based summaries for informational purposes only. We do not host, distribute, or endorse vendor documentation. All certificates of analysis, GMP certificates, and vendor communications must be requested and verified directly by the buyer. Nothing on this platform constitutes legal, medical, or professional advice. Users are solely responsible for verifying vendor credentials and ensuring compliance with all applicable local, state, and federal laws before purchasing any research chemicals. Use of this platform constitutes acceptance of full personal responsibility.
Read full disclaimer